Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SCH 527123 in Subjects with Neutrophilic Asthma
2007-005615-26Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of navarixin in neutrophilic asthma, sponsored by Merck & Co. Primary endpoint: Safety based on maintenance of peripheral blood neutrophil count. Started Mar 2008; status: completed.
02
Drugs
navarixin
03
Conditions
neutrophilic asthma
Beyond the preview
Go deeper on 2007-005615-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005615-26.